Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Declines By 9.2%

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 3,470,000 shares, a decline of 9.2% from the September 15th total of 3,820,000 shares. Based on an average daily trading volume, of 381,000 shares, the days-to-cover ratio is currently 9.1 days. Currently, 7.3% of the shares of the company are short sold.

Astria Therapeutics Trading Up 3.8 %

NASDAQ ATXS opened at $11.49 on Wednesday. The stock has a market capitalization of $630.95 million, a price-to-earnings ratio of -4.95 and a beta of 0.71. The business’s 50 day moving average is $11.35 and its two-hundred day moving average is $10.50. Astria Therapeutics has a 12-month low of $4.26 and a 12-month high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Equities analysts forecast that Astria Therapeutics will post -1.72 earnings per share for the current fiscal year.

Institutional Trading of Astria Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers grew its position in Astria Therapeutics by 4.1% during the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock worth $595,000 after buying an additional 2,556 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Astria Therapeutics by 135.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 2,861 shares during the period. Quest Partners LLC increased its stake in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares in the last quarter. American International Group Inc. raised its holdings in Astria Therapeutics by 49.4% during the first quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock worth $346,000 after purchasing an additional 8,122 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Astria Therapeutics by 6.9% during the second quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock worth $1,266,000 after purchasing an additional 8,965 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Oppenheimer raised their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 13th. TD Cowen began coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They issued a “buy” rating and a $35.00 target price for the company. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Friday, September 27th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Astria Therapeutics presently has an average rating of “Buy” and an average price target of $25.20.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.